MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coulthard, S. A.
Right arrow Articles by Hall, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coulthard, S. A.
Right arrow Articles by Hall, A. G.

Vol. 62, Issue 1, 102-109, July 2002

The Effect of Thiopurine Methyltransferase Expression on Sensitivity to Thiopurine Drugs

Sally A. Coulthard, Linda A. Hogarth, Margaret Little, Elizabeth C. Matheson, Christopher P. F. Redfern, Lynne Minto, and Andrew G. Hall

Leukaemia Research Fund Molecular Pharmacology Specialist Programme, Cancer Research Unit (S.A.C., L.A.H., M.L., E.C.M., L.M., A.G.H.), and Medical Molecular Biology Group (C.P.F.R.), Medical School, Newcastle University, Newcastle-upon-Tyne, UK

Although the thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are well established agents for the treatment of leukemia, controversies remain regarding their main mode of action. Previous evidence has suggested that although 6-TG exerts a cytotoxic effect through incorporation of 6-thioguanine nucleotides into newly synthesized DNA (DNA-TGN), an important component of the mode of action of 6-MP is inhibition of purine de novo synthesis (PDNS) through the production of S-methyl-thioinosine 5'-monophosphate (MeTIMP), not formed in cells exposed to 6-TG. We have shown that thiopurine methyltransferase (TPMT) modulates this effect. By transfection of the human TPMT gene using an inducible system to produce a 3.8-fold increase in TPMT activity in the ecdysone receptor 293 embryonic kidney cell line, we demonstrated a 4.4-fold increase in sensitivity to 6-MP. This was associated with a rise in intracellular levels of MeTIMP but a decrease in levels of DNA-TGN. In contrast, induction of TPMT produced a 1.6-fold decrease in sensitivity to 6-TG, a decrease in levels of DNA-TGN, and an increase in levels of methylated thioguanosine monophosphate. Exposure of cells to equitoxic doses of drug showed similar incorporation of DNA-TGN for 6-TG but for 6-MP significantly reduced DNA-TGN in TPMT-induced compared with uninduced cells. For equitoxic doses of 6-MP, equivalent levels of MeTIMP correlated with equivalent amounts of PDNS. These observations suggest that intracellular TGN levels do not give an accurate reflection of cytotoxic potential in patients treated with 6-MP, because different levels of DNA-TGN may be associated with equitoxic effects.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Gen. Virol.Home page
S. Hoover and R. Striker
Thiopurines inhibit bovine viral diarrhea virus production in a thiopurine methyltransferase-dependent manner
J. Gen. Virol., April 1, 2008; 89(4): 1000 - 1009.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
P. Karran
Thiopurines, DNA damage, DNA repair and therapy-related cancer
Br. Med. Bull., February 2, 2007; (2007) ldl020v1.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
U Hindorf, M Lindqvist, C Peterson, P Soderkvist, M Strom, H Hjortswang, A Pousette, and S Almer
Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease
Gut, October 1, 2006; 55(10): 1423 - 1431.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
S. J. Gardiner and E. J. Begg
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Arenas, G. Simpson, C. M. Lewis, E.-M. Shobowale-Bakre, E. Escuredo, L. D. Fairbanks, J. A. Duley, A. Ansari, J. D. Sanderson, and A. M. Marinaki
Genetic Variation in the MTHFR Gene Influences Thiopurine Methyltransferase Activity
Clin. Chem., December 1, 2005; 51(12): 2371 - 2374.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics